Definitive Contract HDTRA106C0042
Award Date
8/2/06
Potential Completion Date
2/1/09
Potential Value
$5.1M
Funding Federal Agency
Defense Threat Reduction Agency
Contracting Federal Agency
Defense Contract Management Agency
Awardee
Microbiotix, Inc.
Ultimate Awardee
Not listed
NAICS Category
Not listed
Set-Aside Type
No Set-Aside Used
Federal Contract Vehicle
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Combination (two or more)
Place of Performance
Worcester, MA 01605, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
113
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award to Microbiotix, Inc., a clinical-stage biopharmaceutical company, was issued by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), under a Broad Agency Announcement (BAA). The $14,195,727 cost-plus-fixed-fee contract supports the development of small molecule pan-filovirus entry inhibitors through lead optimization, selection of a preclinical candidate, and IND-enabling preclinical studies. The...
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the Defense Threat Reduction Agency (DTRA) to Biological Mimetics, Inc., a biotechnology firm that specializes in infectious disease research and vaccine development. The $149,992.18 firm-fixed-price contract is for the delivery of reports related to the SBIR Phase I research. Biological Mimetics has received prior federal grants and contracts to support its work on vaccine candidates against pathogens such as...
This is a $29,009,499.00 cost-plus-fixed-fee definitive contract awarded by the Defense Threat Reduction Agency (DTRA) to Trius Therapeutics, Inc. for the development of broad-spectrum antibacterial therapeutics derived from marine natural products. The contract has an ultimate completion date of September 20, 2014 and was initially awarded on April 21, 2010. The prime contractor, Trius Therapeutics, is a wholly-owned subsidiary of Cubist Pharmaceuticals, Inc. This contract is not associated...
This is a definitive contract awarded by the Defense Threat Reduction Agency (DTRA), a defense agency, to Achaogen, Inc., a for-profit organization, for the preclinical development of novel therapeutics that attenuate virulence of, and inhibit resistance in, Class A bacterial pathogens. The contract has a ceiling value of $24,610,645.00 and was awarded on October 6, 2006, with an ultimate completion date of October 5, 2010. The contract is a cost no fee arrangement and does not have a...
This federal contract award with ID HDTRA107C0018 was made by the Defense Threat Reduction Agency (DTRA), a defense agency, to the Texas Biomedical Research Institute, doing business as the Southwest Foundation For Biomedical Research. The $1,425,882.00 cost-plus-fixed-fee contract is for the base year period with an ultimate completion date of February 25, 2011. The contract was awarded on February 26, 2007 and did not have a set-aside designation. The Texas Biomedical Research Institute is a...
This federal contract award from the Defense Threat Reduction Agency (DTRA) to Vitrivax, Inc. is for the optimization and production of single-shot vaccines for melioidosis and glanders. The $29,845,804.71 definitive contract has a cost-plus-fixed-fee pricing type and an ultimate completion date of January 11, 2028. The contract was awarded under a Broad Agency Announcement solicitation that sought innovative research and development projects focused on countering weapons of mass destruction,...
This is a federal contract award to Novartis Vaccines And Diagnostics, Inc. by the Defense Threat Reduction Agency (DTRA), a defense agency. The contract is for research and development in biotechnology, with a ceiling value of $48,276,293.00. The contract type is an Other Transaction Agreement, with a pricing type of Other. The contract has an ultimate completion date of January 9, 2013 and was originally awarded on July 10, 2007. The place of performance is Oakland, California. The contract...
This is a federal contract award from the Defense Threat Reduction Agency (DTRA), a defense agency, to Memed Diagnostics LTD, a for-profit limited liability company located in Israel. The contract has a ceiling value of $10,373,294.17 and is a cost-plus-fixed-fee definitive contract with a period of performance ending on September 30, 2020. The contract was awarded on January 1, 2017 and was not set aside. The purpose of the contract is not provided, but DTRA's mission is to counter and deter...
This is a $3,624,974 cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the Department of Health and Human Services, to Trius Therapeutics, Inc. for the "DEVELOPMENT OF THERAPEUTIC MEDICAL COUNTERMEASURES FOR BIODEFENSE AND EMERGING INFECTIOUS DISEASES". The contract has a period of performance from September 16, 2013 to September 15, 2015, with a ceiling value of $845,876.06. There is no set-aside for this award....
This is a federal contract awarded by the Defense Threat Reduction Agency (DTRA), a defense agency, to Mapp Biopharmaceutical, Inc., a biotechnology company specializing in the development of antibody-based therapeutics and medical countermeasures against infectious diseases and biothreats. The contract, valued at $6,173,324.00, is for research and development services during the base period, with a period of performance ending on August 31, 2017. The contract is a Cost Plus Fixed Fee Definitive...